SCHEMBL5065888

SCHEMBL5065888

COc1ccc(N(c2ccnc(N)n2)C(c2cccnc2)c2cccnc2)cn1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSP90AA1 P07900 1/20 0.36
HSP90AB1 P08238 1/20 0.36
PTK2 Q05397 1/20 0.36
CYP19A1 P11511 1/20 0.35
PIK3CA P42336 3/20 0.35
PIK3CD O00329 2/20 0.35
PIK3CB P42338 2/20 0.35
PIK3CG P48736 2/20 0.35
MTOR P42345 1/20 0.34
HRH4 Q9H3N8 7/20 0.34
DYRK3 O43781 1/20 0.34
CCNT1 O60563 1/20 0.34
CDK9 P50750 1/20 0.34
DYRK1A Q13627 1/20 0.34
DYRK2 Q92630 1/20 0.34
DYRK1B Q9Y463 1/20 0.34
HCRTR1 O43613 2/20 0.33
HCRTR2 O43614 2/20 0.33
HRH3 Q9Y5N1 1/20 0.33
POLB P06746 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4469190 0.88 CYP19A1 (0.36) CYP19A1PIK3CAPIK3CDPIK3CBPIK3CG
SCHEMBL4462686 0.86 CYP19A1 (0.40) CYP19A1HCRTR1HCRTR2KCNA5HTR6
SCHEMBL13971749 0.84 HSP90AA1 (0.43) HSP90AA1HSP90AB1PTK2HRH4HRH3
SCHEMBL4461835 0.84 CYP19A1 (0.40) CYP19A1HCRTR1HCRTR2POLBKCNA5
SCHEMBL4459564 0.83 CYP19A1 (0.36) CYP19A1HCRTR1HCRTR2KCNA5HTR6
SCHEMBL4461880 0.83 KCNA5 (0.35) CYP19A1PIK3CAPIK3CDPIK3CBPIK3CG
SCHEMBL14435718 0.82 PDE4D (0.37) CYP19A1HCRTR1HCRTR2POLBKCNA5
SCHEMBL4457212 0.82 KCNA5 (0.42) CYP19A1HCRTR1HCRTR2POLBKCNA5
SCHEMBL4458245 0.81 CYP19A1 (0.35) CYP19A1HCRTR1HCRTR2POLBKCNA5
SCHEMBL4460609 0.79 KCNA5 (0.46) CYP19A1HCRTR1HCRTR2KCNA5HTR6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1981507-A2 POTASSIUM CHANNEL INHIBITORS Merck & Co., Inc. (US) 2008-10-22 EP claimed
WO-2007089679-A2 POTASSIUM CHANNEL INHIBITORS MERCK & CO., INC. (US) 2007-08-09 WO claimed
US-20090030043-A1 Potassium Channel Inhibitors MERCK SHARP & DOHME CORP. 2009-01-29 US disclosed
EP-1981507-A2 POTASSIUM CHANNEL INHIBITORS Merck & Co., Inc. (US) 2008-10-22 EP disclosed
WO-2007089679-A2 POTASSIUM CHANNEL INHIBITORS MERCK & CO., INC. (US) 2007-08-09 WO disclosed
WO-2007089679-A2 POTASSIUM CHANNEL INHIBITORS MERCK & CO., INC. (US) 2007-08-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090030043-A1 Potassium Channel Inhibitors KCNJ2, KCNH2, KCNH3 HSP90AA1 4203/4885HSP90AB1 3842/4885PTK2 1900/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.